Vertex EVP sells 596 shares in planned trade

Vertex Pharmaceuticals executive Dr. Carmen Bozic, EVP and CMO, sold 596 shares of Common Stock in an open-market transaction.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Dr. Carmen Bozic, EVP and CMO, sold 596 shares of Common Stock in an open-market transaction. The sale took place on June 26, 2026 at a price of $482.50 per share, for total proceeds of about $287,570.

The transaction was made under a company-approved Rule 10b5-1 trading plan that Dr. Bozic entered into on November 20, 2025, indicating it was pre‑scheduled rather than opportunistic. Following the sale, she directly owns 15,337 shares of Vertex common stock.

Insider Trade Summary 10b5-1

Net Seller: 596 shares

Net Sell 1 txn

Insider Bozic Carmen

Role EVP and CMO

Sold 596 shs ($288K)

Type	Security	Shares	Price	Value
Sale	Common Stock	596	$482.50	$288K

Holdings After Transaction: Common Stock — 15,337 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Key Figures

Shares sold: 596 shares Sale price: $482.50 per share Transaction value: $287,570 +1 more

4 metrics

Shares sold 596 shares Open-market sale on June 26, 2026

Sale price $482.50 per share Common Stock transaction price

Transaction value $287,570 Approximate proceeds from selling 596 shares

Shares owned after sale 15,337 shares Direct ownership following the transaction

Key Terms

Rule 10b5-1, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 regulatory

"company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vertex (VRTX) report for Dr. Carmen Bozic?

Vertex reported that Dr. Carmen Bozic, EVP and CMO, sold 596 shares of Common Stock. The shares were sold in an open-market transaction at $482.50 per share, and she continues to hold 15,337 shares directly afterward.

How large was Dr. Carmen Bozic’s recent VRTX stock sale?

Dr. Bozic sold 596 Vertex shares at $482.50 each, totaling roughly $287,570. This represents only a small portion of her holdings, as she still directly owns 15,337 shares of Vertex common stock following the transaction.

Was the latest VRTX insider sale by Dr. Bozic under a Rule 10b5-1 plan?

Yes. The sale was executed under a company-approved Rule 10b5-1 trading plan entered on November 20, 2025. Such plans pre-schedule trades, making the timing more routine and less reflective of short-term views on Vertex’s stock.

What role does Dr. Carmen Bozic hold at Vertex (VRTX)?

Dr. Carmen Bozic serves as Executive Vice President and Chief Medical Officer at Vertex. Her Form 4 filing shows the recent open-market sale of 596 common shares while retaining 15,337 shares of direct ownership in the company.

How many VRTX shares does Dr. Bozic hold after the reported sale?

After selling 596 shares, Dr. Bozic directly holds 15,337 Vertex common shares. This post-transaction figure indicates that the reported sale was relatively modest compared with her remaining position in the company’s stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:09 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bozic Carmen

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP and CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/26/2026		S(1)		596	D	$482.5	15,337	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)